NEWPONG presents FDA-cleared LSSA (NP-200) at ASLMS 2026
Source publication date
Site published
FDA describes a surgical ultrasonic system that fragments and emulsifies subcutaneous fat for aesthetic contouring, with use in plastic/reconstructive and orthopedic surgery. This is not external non-invasive HIFU or electrical/magnetic muscle stimulation.
The manufacturer framed ASLMS participation as a U.S.-market milestone. Exhibition activity does not establish clinical superiority or obesity-treatment efficacy.
Summary
NEWPONG reported its U.S. exhibition introduction on May 11. FDA documentation independently confirms the April 3 K252495 decision for LSSA (NP-200).
Editorial view
Editorial view: a model-specific regulatory record makes this a concrete Korean-device market-entry story. Invasiveness, surgical setting and labeled indication must be compared separately from non-invasive contouring.
Evidence and limitations
510(k) is a substantial-equivalence determination, not PMA approval or proof of weight-loss efficacy. U.S. clearance does not establish Korean, Chinese or Japanese authorization.